CJC-1295

CJC-1295 derives from growth hormone-releasing hormone. The native hormone is 44 residues, but the first 29 constitute the shortest fragment described in the literature as retaining activity, and that fragment — GRF(1-29) — is the scaffold here. Several residues are substituted to resist the enzymatic cleavage that rapidly clears the native sequence.

The critical purchasing detail is that two different molecules are sold under this name. CJC-1295 with DAC includes a drug affinity complex, a reactive linker that allows the peptide to bind covalently to circulating albumin and dramatically extends its half-life. CJC-1295 without DAC omits that linker and is, in practice, modified GRF(1-29).

These are not interchangeable. They differ in molecular weight, in chromatographic behaviour and in the literature that applies to them. A certificate that says only CJC-1295 without specifying the DAC status is incomplete, and a laboratory should resolve that ambiguity before the material enters an experiment.

Research on GHRH analogues covers receptor binding and signalling at the GHRH receptor, pulsatile secretion dynamics in animal models, and the pharmacokinetic engineering question of how to extend the lifetime of a rapidly cleared peptide. The DAC approach is itself a subject of the medicinal-chemistry literature.

CJC-1295 is frequently studied and supplied alongside ipamorelin because the two act on different receptors — GHRH receptor and ghrelin receptor respectively — and the interaction between those pathways is the reason combined preparations exist in research contexts.

Growth hormone-releasing factors and their analogues are prohibited in sport under the World Anti-Doping Agency list. Any laboratory connected to athlete populations or anti-doping work should account for that in how the material is controlled and logged.

Release is by chromatographic analysis against a stated purity specification, with the dual-component kit released under LC-MS. Mass analysis is particularly valuable for this compound because it is the most direct way to distinguish the DAC and non-DAC forms, which differ substantially in mass.

The DAC linker introduces a second consideration that plain peptides do not have. It is a reactive group by design — that reactivity is how albumin binding is achieved — so a DAC-form lot can carry adducts and hydrolysis products that a non-DAC lot would not. A certificate for the DAC form should therefore be read as describing a more complex material, and the related-substance profile is worth reviewing rather than only the main-peak figure.

Store sealed lyophilised vials at 2–8 °C, protected from light and moisture, and equilibrate to room temperature before opening. After reconstitution, prepare close to the point of use, log diluent and date, and minimise freeze-thaw cycles.

CJC-1295 is not an approved medicine in the United Arab Emirates or elsewhere and is not supplied for human or veterinary use. Orders are accepted against a research-use declaration retained in the order record.

VaultLabs catalogs this compound within a dual-vial kit alongside ipamorelin. Laboratories evaluating the kit should review the documentation for each component separately rather than treating a single figure as describing both.

Pituitary cell culture models

GH release assay systems

GHRH receptor binding studies

Combination protocol literature (with GHRP peptides)

2–8 °C (lyophilized, sealed)

2–8 °C sealed. Document batch and reconstitution for audit trails in institutional inventory systems.

Lyophilized analogs degrade with moisture exposure. Maintain sealed cold storage until reconstitution under aseptic conditions.